Neurogene Inc. Payments for Restructuring
Neurogene Inc. (NGNE) reported Payments for Restructuring of $2.69 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2023-11-14
- Neurogene Inc. payments for restructuring for the quarter ending 2023-09-30 was $416.00K.
- Neurogene Inc. payments for restructuring for the quarter ending 2023-06-30 was $1.44M.
- Neurogene Inc. payments for restructuring for the quarter ending 2023-03-31 was $834.00K.
- Neurogene Inc. payments for restructuring for the quarter ending 2018-09-30 was $3.30M.
- Neurogene Inc. payments for restructuring for fiscal 2022 was $366.00K.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2023-09-30 | $416.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.86M derived: sum of 2 quarters · filed 2023-11-14 | $2.69M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.28M 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $834.00K 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $366.00K 10-K · filed 2023-03-20 | |||
| 2018-09-30 | $3.30M 10-Q · filed 2018-11-07 | $3.34M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |